Korean Circulation Journal

  • 제54권10호
  • /
  • Pages.591-602
  • /
  • 2024
  • /
  • 1738-5520(pISSN)
  • /
  • 1738-5555(eISSN)
대한심장학회 (The Korean Society of Cardiology)
권호 표지
DOI QR코드

DOI QR Code

Regional Differences in the Epidemiology of Heart Failure

  • 투고 : 2024.06.19
  • 심사 : 2024.07.01
  • 발행 : 2024.10.01
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

Heart failure (HF) epidemiology, patient characteristics, and clinical outcomes exhibit substantial regional variations, reflecting diverse etiologies and health system capacities. This review comprehensively analyses these variations, drawing on data from recent global registries and clinical trials. Our review indicates that ischemic and hypertensive heart diseases are prevalent globally but differ in dominance depending on the region. Notably, regions such as Africa and Latin America show higher instances of HF from hypertensive heart disease and Chagas cardiomyopathy, respectively. Moreover, disparities in age and comorbidity profiles across regions highlight younger populations with HF in lower-income countries compared to older populations in high-income regions. This review also highlights the global disparity in guideline-directed medical and device therapy, underscoring significant underuse in lower-income regions. These insights emphasize the need for targeted HF management strategies considering regional clinical and demographic characteristics to enhance global HF care and outcomes.

키워드

참고문헌

  1. GBD 2017 Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet 2018;392:1789-858. https://doi.org/10.1016/S0140-6736(18)32279-7
  2. Tromp J, Bamadhaj S, Cleland JG, et al. Post-discharge prognosis of patients admitted to hospital for heart failure by world region, and national level of income and income disparity (REPORT-HF): a cohort study. Lancet Glob Health 2020;8:e411-22. https://doi.org/10.1016/S2214-109X(20)30004-8
  3. Wei S, Miranda JJ, Mamas MA, et al. Sex differences in the etiology and burden of heart failure across country income level: analysis of 204 countries and territories 1990-2019. Eur Heart J Qual Care Clin Outcomes 2023;9:662-72.
  4. Agarwal A, Tromp J, Almahmeed W, et al. Toward a universal definition of etiologies in heart failure: categorizing causes and advancing registry science. Circ Heart Fail 2024;17:e011095.
  5. Tromp J, Ferreira JP, Janwanishstaporn S, et al. Heart failure around the world. Eur J Heart Fail 2019;21:1187-96. https://doi.org/10.1002/ejhf.1585
  6. Ang N, Chandramouli C, Yiu K, Lawson C, Tromp J. Heart failure and multimorbidity in Asia. Curr Heart Fail Rep 2023;20:24-32. https://doi.org/10.1007/s11897-023-00585-2
  7. Yogeswaran V, Hidano D, Diaz AE, et al. Regional variations in heart failure: a global perspective. Heart 2023;110:11-8. https://doi.org/10.1136/heartjnl-2022-321295
  8. Walli-Attaei M, Joseph P, Johansson I, et al. Characteristics, management, and outcomes in women and men with congestive heart failure in 40 countries at different economic levels: an analysis from the Global Congestive Heart Failure (G-CHF) registry. Lancet Glob Health 2024;12:e396-405.
  9. G-CHF Investigators, Joseph P, Roy A, et al. Global variations in heart failure etiology, management, and outcomes. JAMA 2023;329:1650-61. https://doi.org/10.1001/jama.2023.5942
  10. Gerhardt T, Gerhardt LM, Ouwerkerk W, et al. Multimorbidity in patients with acute heart failure across world regions and country income levels (REPORT-HF): a prospective, multicentre, global cohort study. Lancet Glob Health 2023;11:e1874-84.
  11. Bragazzi NL, Zhong W, Shu J, et al. Burden of heart failure and underlying causes in 195 countries and territories from 1990 to 2017. Eur J Prev Cardiol 2021;28:1682-90. https://doi.org/10.1093/eurjpc/zwaa147
  12. Ogunniyi MO, Commodore-Mensah Y, Ferdinand KC. Race, ethnicity, hypertension, and heart disease: JACC Focus Seminar 1/9. J Am Coll Cardiol 2021;78:2460-70. https://doi.org/10.1016/j.jacc.2021.06.017
  13. Martinez F, Perna E, Perrone SV, Liprandi AS. Chagas disease and heart failure: an expanding issue worldwide. Eur Cardiol 2019;14:82-8. https://doi.org/10.15420/ecr.2018.30.2
  14. Zhang J, Liu H, Bu X, et al. The burden of alcoholic cardiomyopathy in China and different regions around the world. J Glob Health 2022;12:04041.
  15. Stewart S, Wilkinson D, Hansen C, et al. Predominance of heart failure in the Heart of Soweto Study cohort: emerging challenges for urban African communities. Circulation 2008;118:2360-7.  https://doi.org/10.1161/CIRCULATIONAHA.108.786244
  16. Dokainish H, Teo K, Zhu J, et al. Global mortality variations in patients with heart failure: results from the International Congestive Heart Failure (INTER-CHF) prospective cohort study. Lancet Glob Health 2017;5:e665-72. https://doi.org/10.1016/S2214-109X(17)30196-1
  17. Damasceno A, Mayosi BM, Sani M, et al. The causes, treatment, and outcome of acute heart failure in 1006 Africans from 9 countries. Arch Intern Med 2012;172:1386-94. https://doi.org/10.1001/archinternmed.2012.3310
  18. Tromp J, Tay WT, Ouwerkerk W, et al. Multimorbidity in patients with heart failure from 11 Asian regions: a prospective cohort study using the ASIAN-HF registry. PLoS Med 2018;15:e1002541.
  19. Chandramouli C, Teng TK, Tay WT, et al. Impact of diabetes and sex in heart failure with reduced ejection fraction patients from the ASIAN-HF registry. Eur J Heart Fail 2019;21:297-307. https://doi.org/10.1002/ejhf.1358
  20. Tromp J, Ouwerkerk W, Cleland JG, et al. Global differences in burden and treatment of ischemic heart disease in acute heart failure: REPORT-HF. JACC Heart Fail 2021;9:349-59. https://doi.org/10.1016/j.jchf.2020.12.015
  21. Swarnata A, Kamilah FZ, Wisana IDGK, Meilissa Y, Kusnadi G. Crowding-out effect of tobacco consumption in Indonesia. Tob Control 2024;33:s81-7. https://doi.org/10.1136/tc-2022-057843
  22. Dai X, Gakidou E, Lopez AD. Evolution of the global smoking epidemic over the past half century: strengthening the evidence base for policy action. Tob Control 2022;31:129-37. https://doi.org/10.1136/tobaccocontrol-2021-056535
  23. Ordunez P, Martinez R, Soliz P, Giraldo G, Mujica OJ, Nordet P. Rheumatic heart disease burden, trends, and inequalities in the Americas, 1990-2017: a population-based study. Lancet Glob Health 2019;7:e1388-97. https://doi.org/10.1016/S2214-109X(19)30360-2
  24. Chioncel O, Mebazaa A, Harjola VP, et al. Clinical phenotypes and outcome of patients hospitalized for acute heart failure: the ESC Heart Failure Long-Term Registry. Eur J Heart Fail 2017;19:1242-54. https://doi.org/10.1002/ejhf.890
  25. Chioncel O, Lainscak M, Seferovic PM, et al. Epidemiology and one-year outcomes in patients with chronic heart failure and preserved, mid-range and reduced ejection fraction: an analysis of the ESC Heart Failure Long-Term Registry. Eur J Heart Fail 2017;19:1574-85. https://doi.org/10.1002/ejhf.813
  26. Crespo-Leiro MG, Anker SD, Maggioni AP, et al. European Society of Cardiology Heart Failure Long-Term Registry (ESC-HF-LT): 1-year follow-up outcomes and differences across regions. Eur J Heart Fail 2016;18:613-25. https://doi.org/10.1002/ejhf.566
  27. Tromp J, Ouwerkerk W, Cleland JG, et al. A global perspective of racial differences and outcomes in patients presenting with acute heart failure. Am Heart J 2022;243:11-4. https://doi.org/10.1016/j.ahj.2021.09.001
  28. Pfeffer MA, Claggett B, Assmann SF, et al. Regional variation in patients and outcomes in the Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist (TOPCAT) trial. Circulation 2015;131:34-42. https://doi.org/10.1161/CIRCULATIONAHA.114.013255
  29. Metra M, Mentz RJ, Hernandez AF, et al. Geographic differences in patients in a global acute heart failure clinical trial (from the ASCEND-HF trial). Am J Cardiol 2016;117:1771-8. https://doi.org/10.1016/j.amjcard.2016.03.002
  30. Mentz RJ, Cotter G, Cleland JG, et al. International differences in clinical characteristics, management, and outcomes in acute heart failure patients: better short-term outcomes in patients enrolled in Eastern Europe and Russia in the PROTECT trial. Eur J Heart Fail 2014;16:614-24. https://doi.org/10.1002/ejhf.92
  31. Greene SJ, Fonarow GC, Solomon SD, et al. Global variation in clinical profile, management, and postdischarge outcomes among patients hospitalized for worsening chronic heart failure: findings from the ASTRONAUT trial. Eur J Heart Fail 2015;17:591-600. https://doi.org/10.1002/ejhf.280
  32. Blair JE, Zannad F, Konstam MA, et al. Continental differences in clinical characteristics, management, and outcomes in patients hospitalized with worsening heart failure results from the EVEREST (Efficacy of Vasopressin Antagonism in Heart Failure: Outcome Study with Tolvaptan) program. J Am Coll Cardiol 2008;52:1640-8. https://doi.org/10.1016/j.jacc.2008.07.056
  33. Tromp J, Claggett BL, Liu J, et al. Global differences in heart failure with preserved ejection fraction: the PARAGON-HF trial. Circ Heart Fail 2021;14:e007901.
  34. Tromp J, Ezekowitz JA, Ouwerkerk W, et al. Global variations according to sex in patients hospitalized for heart failure in the REPORT-HF registry. JACC Heart Fail 2023;11:1262-71. https://doi.org/10.1016/j.jchf.2023.06.028
  35. Kristensen SL, Martinez F, Jhund PS, et al. Geographic variations in the PARADIGM-HF heart failure trial. Eur Heart J 2016;37:3167-74. https://doi.org/10.1093/eurheartj/ehw226
  36. Sharma A, Zhao X, Hammill BG, et al. Trends in noncardiovascular comorbidities among patients hospitalized for heart failure: insights from the Get With The Guidelines-Heart Failure registry. Circ Heart Fail 2018;11:e004646.
  37. Lam CS, Santema BT, Voors AA. Atrial fibrillation in heart failure: a common and deadly combination. JACC Heart Fail 2017;5:575-7. https://doi.org/10.1016/j.jchf.2017.05.010
  38. Shen L, Ramires F, Martinez F, et al. Contemporary characteristics and outcomes in Chagasic heart failure compared with other nonischemic and ischemic cardiomyopathy. Circ Heart Fail 2017;10:e004361. 
  39. Sulaiman K, Panduranga P, Al-Zakwani I, et al. Clinical characteristics, management, and outcomes of acute heart failure patients: observations from the Gulf Acute Heart Failure Registry (Gulf CARE). Eur J Heart Fail 2015;17:374-84. https://doi.org/10.1002/ejhf.245
  40. MacDonald MR, Tay WT, Teng TK, et al. Regional variation of mortality in heart failure with reduced and preserved ejection fraction across Asia: outcomes in the ASIAN-HF registry. J Am Heart Assoc 2020;9:e012199.
  41. Lam CS, Anand I, Zhang S, et al. Asian Sudden Cardiac Death in Heart Failure (ASIAN-HF) registry. Eur J Heart Fail 2013;15:928-36. https://doi.org/10.1093/eurjhf/hft045
  42. Tromp J, MacDonald MR, Tay WT, et al. Heart failure with preserved ejection fraction in the young. Circulation 2018;138:2763-73. https://doi.org/10.1161/CIRCULATIONAHA.118.034720
  43. Gillott RG, Willan K, Kain K, Sivananthan UM, Tayebjee MH. South Asian ethnicity is associated with a lower prevalence of atrial fibrillation despite greater prevalence of established risk factors: a population-based study in Bradford Metropolitan District. Europace 2017;19:356-63.
  44. Matsue Y, Kamiya K, Saito H, et al. Prevalence and prognostic impact of the coexistence of multiple frailty domains in elderly patients with heart failure: the FRAGILE-HF cohort study. Eur J Heart Fail 2020;22:2112-9. https://doi.org/10.1002/ejhf.1926
  45. Spence JD, Rayner BL. Hypertension in blacks. Hypertension 2018;72:263-9. https://doi.org/10.1161/HYPERTENSIONAHA.118.11064
  46. Tromp J, Ouwerkerk W, Teng TK, et al. Global disparities in prescription of guideline-recommended drugs for heart failure with reduced ejection fraction. Eur Heart J 2022;43:2224-34. https://doi.org/10.1093/eurheartj/ehac103
  47. Tromp J, Ouwerkerk W, van Veldhuisen DJ, et al. A systematic review and network meta-analysis of pharmacological treatment of heart failure with reduced ejection fraction. JACC Heart Fail 2022;10:73-84. https://doi.org/10.1016/j.jchf.2021.09.004
  48. Sud M, Yu B, Wijeysundera HC, et al. Associations between short or long length of stay and 30-day readmission and mortality in hospitalized patients with heart failure. JACC Heart Fail 2017;5:578-88. https://doi.org/10.1016/j.jchf.2017.03.012
  49. Wang SY, Valero-Elizondo J, Ali HJ, et al. Out-of-pocket annual health expenditures and financial toxicity from healthcare costs in patients with heart failure in the United States. J Am Heart Assoc 2021;10:e022164.
  50. Out-of-pocket expenditure (% of current health expenditure) - Latin America & Caribbean, North America, European Union, East Asia & Pacific [Internet]. Washington, D.C.: World Bank Group; 2024 [cited 2024 June 4]. Available from: https://data.worldbank.org/indicator/SH.XPD.OOPC.CH.ZS?locations=ZJ-XU-EU-Z4. 
  51. Hertz JT, Sakita FM, Kweka GL, et al. Healthcare-seeking behaviour, barriers to care and predictors of symptom improvement among patients with cardiovascular disease in northern Tanzania. Int Health 2022;14:373-80. https://doi.org/10.1093/inthealth/ihz095
  52. Birlie TA, Amare AT, Agegn SB, et al. Treatment seeking delay and associated factors in adult heart failure patients admitted to Debre Tabor comprehensive specialized hospital, North West, Ethiopia. Heliyon (Lond) 2023;10:e23348.
  53. Bernard D, Fang Z. Financial burdens and barriers to care among nonelderly adults with heart disease: 2010-2015. J Am Heart Assoc 2019;8:e008831.
  54. Cheng RK, Cox M, Neely ML, et al. Outcomes in patients with heart failure with preserved, borderline, and reduced ejection fraction in the Medicare population. Am Heart J 2014;168:721-30. https://doi.org/10.1016/j.ahj.2014.07.008
  55. Adams KF Jr, Fonarow GC, Emerman CL, et al. Characteristics and outcomes of patients hospitalized for heart failure in the United States: rationale, design, and preliminary observations from the first 100,000 cases in the Acute Decompensated Heart Failure National Registry (ADHERE). Am Heart J 2005;149:209-16. https://doi.org/10.1016/j.ahj.2004.08.005
  56. Atherton JJ, Hayward CS, Wan Ahmad WA, et al. Patient characteristics from a regional multicenter database of acute decompensated heart failure in Asia Pacific (ADHERE International-Asia Pacific). J Card Fail 2012;18:82-8. https://doi.org/10.1016/j.cardfail.2011.09.003
  57. Filippatos G, Angermann CE, Cleland JG, et al. Global differences in characteristics, precipitants, and initial management of patients presenting with acute heart failure. JAMA Cardiol 2020;5:401-10. https://doi.org/10.1001/jamacardio.2019.5108
  58. Ouwerkerk W, Tromp J, Cleland JG, et al. Association of time-to-intravenous furosemide with mortality in acute heart failure: data from REPORT-HF. Eur J Heart Fail 2023;25:43-51. https://doi.org/10.1002/ejhf.2708
  59. Greene SJ, Butler J, Albert NM, et al. Medical therapy for heart failure with reduced ejection fraction: the CHAMP-HF registry. J Am Coll Cardiol 2018;72:351-66. https://doi.org/10.1016/j.jacc.2018.04.070
  60. Ouwerkerk W, Voors AA, Anker SD, et al. Determinants and clinical outcome of uptitration of ACE-inhibitors and beta-blockers in patients with heart failure: a prospective European study. Eur Heart J 2017;38:1883-90.  https://doi.org/10.1093/eurheartj/ehx026
  61. Teng TK, Tromp J, Tay WT, et al. Prescribing patterns of evidence-based heart failure pharmacotherapy and outcomes in the ASIAN-HF registry: a cohort study. Lancet Glob Health 2018;6:e1008-18. https://doi.org/10.1016/S2214-109X(18)30306-1
  62. Komajda M, Anker SD, Cowie MR, et al. Physicians' adherence to guideline-recommended medications in heart failure with reduced ejection fraction: data from the QUALIFY global survey. Eur J Heart Fail 2016;18:514-22. https://doi.org/10.1002/ejhf.510
  63. Chen YJ, Zhang XY, Tang X, Yan JQ, Qian MC, Ying XH. How do inpatients' costs, length of stay, and quality of care vary across age groups after a new case-based payment reform in China? An interrupted time series analysis. BMC Health Serv Res 2023;23:160.
  64. Packer DL, Prutkin JM, Hellkamp AS, et al. Impact of implantable cardioverter-defibrillator, amiodarone, and placebo on the mode of death in stable patients with heart failure: analysis from the sudden cardiac death in heart failure trial. Circulation 2009;120:2170-6. https://doi.org/10.1161/CIRCULATIONAHA.109.853689
  65. Chia YM, Teng TK, Tan ES, et al. Disparity between indications for and utilization of implantable cardioverter defibrillators in Asian patients with heart failure. Circ Cardiovasc Qual Outcomes 2017;10:e003651.
  66. Sanders GD, Hlatky MA, Owens DK. Cost-effectiveness of implantable cardioverter-defibrillators. N Engl J Med 2005;353:1471-80. https://doi.org/10.1056/NEJMsa051989
  67. Lau CP, Tse HF, Mond HG. The impact of reimbursement on the usage of pacemakers, implantable cardioverter defibrillators and radiofrequency ablation. J Interv Card Electrophysiol 2006;17:177-81. https://doi.org/10.1007/s10840-006-9076-7